This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Poola, I. Articles by Liu, A. Search for Related Content PubMed PubMed Citation Articles by Poola, I. Articles by Liu, A.

Estrogen Receptor –Negative Breast Cancer Tissues Express Significant Levels of Estrogen-Independent Transcription Factors, ERß1 and ERß5: Potential Molecular Targets for Chemoprevention

Authors' Affiliations: Departments of ¹ Biochemistry and Molecular Biology, ² Surgical Oncology, and ³ Pathology, Howard University College of Medicine, Washington, District of Columbia; ⁴ Breast Center, Baylor College of Medicine, Houston, Texas; and ⁵ Biometry and Mathematical Statistics Branch, National Institutes of Child Health and Human Development, NIH, Bethesda, Maryland

Requests for reprints: Indira Poola, Department of Biochemistry and Molecular Biology, Howard University School of Medicine, 520 W Street Northwest, Washington, DC 20059. Phone: 202-806-5554; Fax: 202-806-5553/5784; E-mail: ipoola{at}howard.edu.

We have investigated the expression of two estrogen receptor ß (ERß) isoforms, ERß1 and ERß5, which activate gene transcription independent of estrogen or growth factors, in ER-negative breast cancer tissues. We report here, for the first time, that ER-negative tissues express significant levels of ERß1 and ERß5, and their expression levels are not different from levels in ER positive tumors. However, significant differences exist between the two racial groups, African American and Caucasian, in that the patients from the former group express higher levels of ERß1 and ERß5 but not ER. These two transcription factors could be potential molecular targets for designing chemopreventive drugs to treat ER-negative breast cancers.

This article has been cited by other articles:

				V. Speirs, A. R. Green, T. A. Hughes, I. O. Ellis, P. T.K. Saunders, and A. M. Shaaban Clinical Importance of Estrogen Receptor {beta} Isoforms in Breast Cancer J. Clin. Oncol., December 10, 2008; 26(35): 5825 - 5825. [Full Text] [PDF]

				A. M. Shaaban, A. R. Green, S. Karthik, Y. Alizadeh, T. A. Hughes, L. Harkins, I. O. Ellis, J. F. Robertson, E. C. Paish, P. T.K. Saunders, et al. Nuclear and Cytoplasmic Expression of ER{beta}1, ER{beta}2, and ER{beta}5 Identifies Distinct Prognostic Outcome for Breast Cancer Patients Clin. Cancer Res., August 15, 2008; 14(16): 5228 - 5235. [Abstract] [Full Text] [PDF]

				I. Poola, J. Abraham, J. J. Marshalleck, Q. Yue, V. B. Lokeshwar, G. Bonney, and R. L. DeWitty Molecular Risk Assessment for Breast Cancer Development in Patients with Ductal Hyperplasias Clin. Cancer Res., February 15, 2008; 14(4): 1274 - 1280. [Abstract] [Full Text] [PDF]

				I. Poola, B. Shokrani, R. Bhatnagar, R. L. DeWitty, Q. Yue, and G. Bonney Expression of Carcinoembryonic Antigen Cell Adhesion Molecule 6 Oncoprotein in Atypical Ductal Hyperplastic Tissues Is Associated with the Development of Invasive Breast Cancer Clin. Cancer Res., August 1, 2006; 12(15): 4773 - 4783. [Abstract] [Full Text] [PDF]